MA53287A - Inhibiteurs de prmt5 - Google Patents

Inhibiteurs de prmt5

Info

Publication number
MA53287A
MA53287A MA053287A MA53287A MA53287A MA 53287 A MA53287 A MA 53287A MA 053287 A MA053287 A MA 053287A MA 53287 A MA53287 A MA 53287A MA 53287 A MA53287 A MA 53287A
Authority
MA
Morocco
Prior art keywords
prmt5 inhibitors
prmt5
inhibitors
Prior art date
Application number
MA053287A
Other languages
English (en)
Inventor
David A Candito
Patrick S Fier
Craig Gibeau
Timothy J Henderson
Chunhui Huang
Jonathan M E Hughes
Shuhei Kawamura
Michelle Machacek
Jean-Laurent Paparin
Ryan Quiroz
Houcine Rahali
Michael H Reutershan
Sulagna Sanyal
Sebastian Schneider
Phieng Siliphaivanh
Steven M Silverman
David L Sloman
Murray Wan
David Witter
Yingchun Ye
Charles S Yeung
Original Assignee
Merck Sharp & Dohme
Msd Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Msd Int Gmbh filed Critical Merck Sharp & Dohme
Publication of MA53287A publication Critical patent/MA53287A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053287A 2018-08-07 2019-08-05 Inhibiteurs de prmt5 MA53287A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862715446P 2018-08-07 2018-08-07
US201962792623P 2019-01-15 2019-01-15
US201962859490P 2019-06-10 2019-06-10

Publications (1)

Publication Number Publication Date
MA53287A true MA53287A (fr) 2022-05-11

Family

ID=69414248

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053287A MA53287A (fr) 2018-08-07 2019-08-05 Inhibiteurs de prmt5

Country Status (11)

Country Link
US (1) US20220363707A1 (fr)
EP (1) EP3833355A4 (fr)
JP (1) JP7446282B2 (fr)
KR (1) KR20210046009A (fr)
CN (1) CN112805006A (fr)
AU (1) AU2019317549A1 (fr)
BR (1) BR112021002267A8 (fr)
CA (1) CA3108388A1 (fr)
MA (1) MA53287A (fr)
MX (1) MX2021001486A (fr)
WO (1) WO2020033288A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006392A2 (pt) 2018-10-05 2021-07-06 Vertex Pharma moduladores da alfa-1 antitripsina
WO2020205867A1 (fr) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composés ciblant prmt5
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CA3141855A1 (fr) * 2019-05-30 2020-12-03 Angex Pharmaceutical, Inc. Composes heterocycliques en tant qu'inhibiteurs de prmt5
WO2021111322A1 (fr) 2019-12-03 2021-06-10 Lupin Limited Analogues nucléosidiques substitués en tant qu'inhibiteurs de prmt5
WO2021202480A1 (fr) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Composés ciblant prmt5
CA3179189A1 (fr) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulateurs d'alpha 1 antitrypsine
WO2023001133A1 (fr) * 2021-07-20 2023-01-26 上海齐鲁制药研究中心有限公司 Inhibiteur de prmt5
EP4384519A1 (fr) 2021-08-13 2024-06-19 Albert-Ludwigs-Universität Freiburg Inhibiteurs à petites molécules spécifiques qui bloquent l'activité et la fonction de la méthyltransférase kmt9
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
WO2024032572A1 (fr) * 2022-08-09 2024-02-15 上海湃隆生物科技有限公司 Nouvel inhibiteur de prmt5 et son utilisation
WO2024101965A1 (fr) * 2022-11-10 2024-05-16 에스케이바이오팜 주식회사 Combinaison pharmaceutique d'inhibiteur de prmt5 et de substance induisant des dommages à l'adn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011160A (es) * 2009-04-22 2012-01-27 Acad Of Science Czech Republic Nuevos nucleosidos de 7-desazapurina para usos terapeuticos.
WO2012170347A1 (fr) * 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Nucléosides bicycliques et composés oligomères préparés à partir de ceux-ci
EP3160477A4 (fr) * 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN105837573B (zh) * 2016-03-28 2018-07-27 江西青峰药业有限公司 一种9-[3a,6-二羟基六氢-1H-环戊二烯并[c]呋喃-4-基]鸟嘌呤的制备方法
WO2018065365A1 (fr) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
EP3665179B1 (fr) * 2017-08-09 2021-06-09 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)

Also Published As

Publication number Publication date
AU2019317549A1 (en) 2021-02-25
JP7446282B2 (ja) 2024-03-08
WO2020033288A1 (fr) 2020-02-13
KR20210046009A (ko) 2021-04-27
BR112021002267A2 (pt) 2021-05-04
MX2021001486A (es) 2021-07-15
US20220363707A1 (en) 2022-11-17
EP3833355A1 (fr) 2021-06-16
CN112805006A (zh) 2021-05-14
JP2022501316A (ja) 2022-01-06
EP3833355A4 (fr) 2022-05-11
BR112021002267A8 (pt) 2023-02-07
CA3108388A1 (fr) 2020-02-13

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
MA53287A (fr) Inhibiteurs de prmt5
MA52413A (fr) Inhibiteurs de cd73
MA52812A (fr) Inhibiteurs de sarm1
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
MA52635A (fr) Inhibiteurs de magl
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA55909A (fr) Inhibiteurs de cdk
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3746446T3 (da) PRC2-inhibitorer
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA52809A (fr) Inhibiteurs de sarm1
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
MA52813A (fr) Inhibiteurs de sarm1
MA51611A (fr) Inhibiteurs de pi4kiiibêta
DK3710457T3 (da) Immunproteasomhæmmere
DK3720840T3 (da) Cathepsinhæmmere
DK3752258T3 (da) Trampolin
DK3587968T3 (da) Fluidsystem
MA49925A (fr) Claie
DE112019000442A5 (de) Ringtilgereinrichtung
NO20181678A1 (no) Rissanviser
JP1628555S (ja) たい焼
JP1628556S (ja) たい焼